Pacira BioSciences, Inc.PCRX

Pacira BioSciences, Inc. Segments Disclosure

10-KFiled Feb 26, 20262 min read
SEGMENT INFORMATION
The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain therapies. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer—who is the Company’s chief operating decision maker, or CODM—manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one operating segment and one reportable segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.
The key measure of the Company is GAAP net income. The CODM uses this measure to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.
There are significant expense categories and amounts that are regularly provided to the CODM. These expense categories differ from what is disclosed in the Company’s financial results. The table below reconciles the significant expense categories provided to the CODM to the Company’s expenses as disclosed under GAAP (in thousands):
Year Ended December 31,
202520242023
Revenues$726,411 $700,966 $674,978 
Less:
Adjusted cost of goods sold (1)
136,780 165,097 173,980 
Adjusted research and development (1)
104,704 74,196 67,563 
Adjusted selling and marketing (1)
226,616 172,015 153,040 
Adjusted general and administrative (1)
100,277 86,385 82,737 
Goodwill impairment— 163,243 — 
Stock-based compensation (1)
57,502 51,171 47,895 
Amortization of acquired intangible assets57,288 57,288 57,288 
Changes in the fair value of contingent consideration(2,175)(4,457)(3,424)
Legal settlement7,000 — — 
Legal judgment(23,148)— — 
Impairment of acquired IPR&D25,866 — — 
Other (2)
16,510 9,399 8,224 
Total operating expenses707,220 774,337 587,303 
Adjusted other income (expense)(1,334)2,747 (9,048)
(Loss) gain on early extinguishment of debt(983)7,518 (16,926)
Total other (expense) income, net(2,317)10,265 (25,974)
Income (loss) before income taxes16,874 (63,106)61,701 
Income tax expense(9,840)(36,454)(19,746)
Net income (loss)$7,034 $(99,560)$41,955 
(1) The adjustments are primarily related to stock-based compensation being noted separately as a line item.
(2) During the year ended December 31, 2025 and 2024, the remaining other operating expenses include restructuring charges. During the years ended December 31, 2025, 2024 and 2023, the remaining other operating expenses include acquisition-related charges.
The measure of segment assets is reported on the Company’s consolidated balance sheet as total assets. Substantially all of the Company’s assets are used to support its mission in delivering innovative, non-opioid pain therapies to transform the lives of patients. For the year ended December 31, 2025, the Company’s long-lived assets were primarily located in the U.S. (83%), and, to a lesser extent, Germany (9%) and the U.K. (8%). For the years ended December 31, 2024 and 2023, the Company’s long-lived assets were substantially located in the U.S. For more information on the Company’s fixed assets, refer to Note 7, Fixed Assets.

Historical Timeline

Fiscal YearFiled
2025Feb 26, 2026Showing above
2024Feb 27, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per SharePP&EGoodwill & IntangiblesLeasesDebtCommitmentsStock CompensationNew StandardsPay vs Performance